![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/07\/20260724_Amgen_Therapeutic_Indications-768x512.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Amgen<\/p>\n Event Type<\/strong><\/p>\n Regulatory Defense Submission (FDA Withdrawal Hearing Request)<\/p>\n Modality<\/strong><\/p>\n Oral Small-Molecule Complement C5a Receptor 1 Antagonist<\/p>\n Asset<\/strong><\/p>\n Tavneos (avacopan)<\/p>\n Target<\/strong><\/p>\n Complement C5a Receptor 1 (C5aR1)<\/p>\n Disease Area<\/strong><\/p>\n Severe Active ANCA-Associated Vasculitis<\/p>\n Amgen submitted data and analyses to FDA on July 23 in support of its request for a hearing on the proposed withdrawal of Tavneos for severe active ANCA-associated vasculitis. The package includes an independently blinded Duke Clinical Research Institute re-adjudication of the pivotal ADVOCATE trial, real-world evidence, meta-analysis, post-marketing safety analyses, and patient and physician perspectives. The re-adjudication confirmed noninferiority versus a prednisone taper at Weeks 26 and 52 but did not reproduce the originally claimed superiority for sustained remission at Week 52. FDA’s proposal remains unresolved and rests on both insufficient substantial evidence and alleged untrue material statements involving post-lock, post-unblinding endpoint changes.<\/p>\n FDA proposed withdrawing Tavneos approval in an April 30 Federal Register notice. The agency cited a lack of substantial evidence of effectiveness and alleged that the application contained untrue statements of material fact concerning database lock, unblinding, and outcome re-adjudication in ADVOCATE.<\/p>\n On July 23, Amgen submitted a defense package seeking a formal hearing and continued U.S. availability. Amgen said it strongly disagrees with FDA’s proposal and argues that the total evidence supports a favorable benefit-risk profile in appropriately selected and monitored patients.<\/p>\n A fully blinded independent re-adjudication by Duke Clinical Research Institute confirmed noninferiority of Tavneos versus a prednisone taper for remission at Week 26 and sustained remission at Week 52. It did not confirm superiority at Week 52, although the treatment effect directionally favored Tavneos.<\/p>\n The submission also incorporates comparative real-world evidence, a meta-analysis, more than 70 published real-world studies involving over 2,200 reported patients, and a liver-focused post-marketing safety evaluation. No final FDA hearing or withdrawal decision has been announced.<\/p>\n This is not a routine label negotiation. FDA has invoked statutory grounds that challenge both the adequacy of the efficacy evidence and the truthfulness of material representations in the application. A hearing would test whether Amgen’s new analyses can overcome those deficiencies; the submission itself does not preserve the approval permanently.<\/p>\n The independent re-adjudication is helpful because it reproduces the noninferiority component under blinded conditions. Its failure to reproduce superiority at Week 52 narrows the efficacy claim and may reinforce FDA’s view that the original post-lock changes affected a clinically important conclusion.<\/p>\n FDA alleges that nine patients’ primary endpoint assessments were re-adjudicated after database lock and trial unblinding and that the original analysis and process were not adequately disclosed. These concerns go beyond statistical sensitivity: they address whether the pivotal evidence was generated and represented in accordance with acceptable research conduct.<\/p>\n A clean independent re-analysis can estimate what the endpoint would have shown under a blinded process, but it cannot retroactively repair the original trial’s governance. FDA must decide whether the reconstructed evidence, together with external data, constitutes substantial evidence for the approved use.<\/p>\n Tavneos has been associated with serious liver injury, including vanishing bile duct syndrome and fatal cases. Hepatic monitoring and patient selection may mitigate risk, but they do not eliminate the need for a clearly demonstrated clinical benefit.<\/p>\n The benefit thesis is reduction of glucocorticoid exposure while maintaining disease control. That is clinically meaningful because prolonged steroid use causes infection, osteoporosis, diabetes, cardiovascular complications, and other morbidity. The decisive question is whether the evidentiary record is reliable and strong enough to justify Tavneos-specific risks.<\/p>\n Avacopan is an oral small-molecule antagonist of complement C5a receptor 1. It is intended to reduce C5a-driven neutrophil activation and vascular inflammation without the broad immunosuppression associated with high-dose glucocorticoids.<\/p>\n In severe granulomatosis with polyangiitis and microscopic polyangiitis, Tavneos is used with standard therapy rather than as a stand-alone replacement for remission-induction immunosuppression. Loss of the product would shift treatment back toward rituximab- or cyclophosphamide-based regimens with greater reliance on corticosteroids.<\/p>\n Amgen acquired ChemoCentryx for approximately $3.7 billion in 2022, principally gaining Tavneos. A U.S. withdrawal would materially impair the transaction’s remaining strategic value and create litigation, reputational, and pharmacovigilance exposure.<\/p>\n The European regulatory position is already adverse: the EMA committee recommended revocation after concluding that ADVOCATE data could not be relied upon and that benefits no longer outweighed risks. Divergent U.S. retention would require FDA to find the supplemented evidence sufficient despite overlapping integrity and safety concerns.<\/p>\n ANCA-associated vasculitis is a group of rare, potentially life-threatening autoimmune disorders in which pathogenic inflammation damages small blood vessels and organs, commonly the kidneys and lungs. Granulomatosis with polyangiitis and microscopic polyangiitis are the principal severe forms.<\/p>\n Tavneos, or avacopan, is an oral complement C5a receptor 1 antagonist approved in the United States in 2021 as adjunctive treatment for adults with severe active ANCA-associated vasculitis in combination with standard therapy. By reducing C5a-mediated neutrophil activation, it is intended to control vascular inflammation and reduce dependence on prolonged glucocorticoid exposure.<\/p>\n Amgen has assembled a substantive defense, but the strongest new result is narrower than the original pivotal claim. Reproducing noninferiority under blinded re-adjudication may support clinical utility; failure to reproduce superiority does not neutralize FDA’s concerns about the original analysis process.<\/p>\n The regulatory question is now whether reconstructed trial evidence plus real-world data can satisfy the substantial-evidence standard while serious hepatic risks remain. The outcome will be an important precedent for post-approval data-integrity enforcement and the evidentiary weight given to independent re-adjudication.<\/p>\n Signal strength:<\/strong> 4\/5 \u2014 High. Importance:<\/strong> High \u2014 a marketed rare-disease therapy faces potential U.S. withdrawal because of pivotal-trial integrity and safety concerns, with a major acquisition’s value and a regulatory precedent at stake. Confidence:<\/strong> High for FDA’s stated withdrawal grounds, Amgen’s submission, the independent re-adjudication result, mechanism, and current approval status; medium for the ultimate outcome because FDA has not ruled on the hearing or final withdrawal.<\/p>\n","protected":false},"excerpt":{"rendered":" Amgen submitted data and analyses to FDA on July 23 in support of its request for a hearing on the proposed withdrawal of Tavneos for severe active ANCA-associated vasculitis. The package includes an independently…<\/p>\n","protected":false},"author":1,"featured_media":2167,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[180,181],"class_list":["post-2145","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-amgen","tag-anca-associated-vasculitis"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2145"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2145\/revisions"}],"predecessor-version":[{"id":2178,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2145\/revisions\/2178"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2167"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Regulatory Interpretation<\/h4>\n
Data-Integrity Analysis<\/h4>\n
Safety and Benefit-Risk<\/h4>\n
Mechanism and Clinical Positioning<\/h4>\n
Strategic and International Implications<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n